Dobutamine tartrate

Cat. No.: HY-15746B: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Dobutamine tartrate is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine tartrate is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine tartrate can increase cardiac output and correct hypoperfusion.

For research use only. We do not sell to patients.

Dobutamine tartrate Chemical Structure

CAS No. : 101626-66-8

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Dobutamine tartrate:

Dobutamine hydrochloride

Other Forms of Dobutamine tartrate:

Dobutamine hydrochloride In-stock
Dobutamine Get quote

3 Publications Citing Use of MCE Dobutamine tartrate

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Adrenergic Receptor Isoform Specific Products:

View All Isoforms

α adrenergic receptor β adrenergic receptor

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vivo

Dobutamine tartrate has a rapid onset of action and a short half-life ^[2].
Dobutamine tartrate (0.15-20 mg/kg; i.p.) results in subsequent increase in the left ventricular function and heart rate acceleration with an increasing dose in wildtype mice^[3].
Dobutamine tartrate results in significant inotropic, lusitropic, and chronotropic cardiac response with a high dose in wildtype mice^[3].
Low doses of Dobutamine tartrate significantly increases inotropic and lusitropic cardiac performance without chronotropic changes in the Tgαq*44 mice^[3].
Dobutamine tartrate increases heart rate only after high doses, but then inotropic and lusitropic cardiac functional reserve is lost^[3].
Dobutamine tartrate increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Tgαq*44 mice (heart failure models)^[3]
Dosage:	0.15 mg/kg, 0.5 mg/kg as a low dose, 1.5 mg/kg, 5 mg/kg, 20 mg/kg as a high dose
Administration:	Intraperitoneal injection
Result:	Induced different response in cardiac function on a low and high dose in mice with with heart failure.

Clinical Trial

Molecular Weight

451.47

Formula

C₂₂H₂₉NO₉

CAS No.

101626-66-8

SMILES

OC1=CC=C(CCNC(C)CCC2=CC=C(O)C=C2)C=C1O.O=C(O)[C@@H](O)[C@H](O)C(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975 Jan;36(1):185-96. [Content Brief]

[2]. Vallet B, et al. Dobutamine: mechanisms of action and use in acute cardiovascular pathology. Ann Cardiol Angeiol (Paris). 1991 Jun;40(6):397-402. [Content Brief]

[3]. Tyrankiewicz U , et al. Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo. J Magn Reson Imaging. 2013 Mar;37(3):669-77. [Content Brief]

[4]. Tibayan FA, et al. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):438-44. [Content Brief]